Report cover image

Global Anti Asthma Short Acting Beta Agonists Market Research Report 2025(Status and Outlook)

Publisher Bosson Research
Published Nov 07, 2025
Length 159 Pages
SKU # BOSS20730236

Description

Report Overview

Short acting beta agonists (SABAs) are bronchodilators primarily used to rapidly alleviate symptoms of acute asthma attacks. This type of drug belongs to phenylethylamine derivatives in terms of chemical structure, and can produce rapid and significant bronchodilator effects by specifically stimulating respiratory smooth muscle β 2-adrenergic receptors. According to the selectivity differences of drugs towards receptor subtypes, they can be divided into non selective β - receptor agonists (such as adrenaline and isoproterenol) and selective β 2 receptor agonists (such as salbutamol and terbutaline). The former acts on β 1 and β 2 receptors and is less commonly used due to cardiac side effects such as tachycardia. The latter exhibits significantly higher selectivity towards β 2 receptors than β 1 receptors, thereby reducing adverse effects on the heart while exerting bronchodilator effects.

The global Anti Asthma Short Acting Beta Agonists market size was estimated at USD 15000.0 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 3.60% during the forecast period.

This report provides a deep insight into the global Anti Asthma Short Acting Beta Agonists market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Anti Asthma Short Acting Beta Agonists Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Anti Asthma Short Acting Beta Agonists market in any manner.

Global Anti Asthma Short Acting Beta Agonists Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

GlaxoSmithKline_x000D_

AstraZeneca_x000D_

Teva Pharmaceutical_x000D_

Pfizer_x000D_

Viatris_x000D_

Novartis_x000D_

Boehringer Ingelheim_x000D_

Sanofi_x000D_

Joincare Pharmaceutical Group Industry_x000D_

Chia Tai Tianqing Pharmaceutical Group_x000D_

Shandong Lunan Pharmaceutical_x000D_

Jiangsu Hengrui Pharmaceuticals_x000D_

Sichuan Puretech Pharmaceutical

Market Segmentation (by Type)

Non-Selective Beta Receptor Agonists_x000D_

Selective Beta 2 Receptor Agonists

Market Segmentation (by Application)

Hospital_x000D_

Clinic_x000D_

Pharmacy_x000D_

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Anti Asthma Short Acting Beta Agonists Market

Overview of the regional outlook of the Anti Asthma Short Acting Beta Agonists Market:

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Anti Asthma Short Acting Beta Agonists Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Anti Asthma Short Acting Beta Agonists, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

Table of Contents

159 Pages
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Anti Asthma Short Acting Beta Agonists
1.2 Key Market Segments
1.2.1 Anti Asthma Short Acting Beta Agonists Segment by Type
1.2.2 Anti Asthma Short Acting Beta Agonists Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Anti Asthma Short Acting Beta Agonists Market Overview
2.1 Global Market Overview
2.1.1 Global Anti Asthma Short Acting Beta Agonists Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Anti Asthma Short Acting Beta Agonists Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Anti Asthma Short Acting Beta Agonists Market Competitive Landscape
3.1 Company Assessment Quadrant
3.2 Global Anti Asthma Short Acting Beta Agonists Product Life Cycle
3.3 Global Anti Asthma Short Acting Beta Agonists Sales by Manufacturers (2020-2025)
3.4 Global Anti Asthma Short Acting Beta Agonists Revenue Market Share by Manufacturers (2020-2025)
3.5 Anti Asthma Short Acting Beta Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Anti Asthma Short Acting Beta Agonists Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Anti Asthma Short Acting Beta Agonists Market Competitive Situation and Trends
3.8.1 Anti Asthma Short Acting Beta Agonists Market Concentration Rate
3.8.2 Global 5 and 10 Largest Anti Asthma Short Acting Beta Agonists Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 Anti Asthma Short Acting Beta Agonists Industry Chain Analysis
4.1 Anti Asthma Short Acting Beta Agonists Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Anti Asthma Short Acting Beta Agonists Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Anti Asthma Short Acting Beta Agonists Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy – April 2025
5.6.3 Global Trade Frictions and Their Impacts to Anti Asthma Short Acting Beta Agonists Market
5.7 ESG Ratings of Leading Companies
6 Anti Asthma Short Acting Beta Agonists Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Anti Asthma Short Acting Beta Agonists Sales Market Share by Type (2020-2025)
6.3 Global Anti Asthma Short Acting Beta Agonists Market Size Market Share by Type (2020-2025)
6.4 Global Anti Asthma Short Acting Beta Agonists Price by Type (2020-2025)
7 Anti Asthma Short Acting Beta Agonists Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Anti Asthma Short Acting Beta Agonists Market Sales by Application (2020-2025)
7.3 Global Anti Asthma Short Acting Beta Agonists Market Size (M USD) by Application (2020-2025)
7.4 Global Anti Asthma Short Acting Beta Agonists Sales Growth Rate by Application (2020-2025)
8 Anti Asthma Short Acting Beta Agonists Market Sales by Region
8.1 Global Anti Asthma Short Acting Beta Agonists Sales by Region
8.1.1 Global Anti Asthma Short Acting Beta Agonists Sales by Region
8.1.2 Global Anti Asthma Short Acting Beta Agonists Sales Market Share by Region
8.2 Global Anti Asthma Short Acting Beta Agonists Market Size by Region
8.2.1 Global Anti Asthma Short Acting Beta Agonists Market Size by Region
8.2.2 Global Anti Asthma Short Acting Beta Agonists Market Size Market Share by Region
8.3 North America
8.3.1 North America Anti Asthma Short Acting Beta Agonists Sales by Country
8.3.2 North America Anti Asthma Short Acting Beta Agonists Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Anti Asthma Short Acting Beta Agonists Sales by Country
8.4.2 Europe Anti Asthma Short Acting Beta Agonists Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Anti Asthma Short Acting Beta Agonists Sales by Region
8.5.2 Asia Pacific Anti Asthma Short Acting Beta Agonists Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Anti Asthma Short Acting Beta Agonists Sales by Country
8.6.2 South America Anti Asthma Short Acting Beta Agonists Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Anti Asthma Short Acting Beta Agonists Sales by Region
8.7.2 Middle East and Africa Anti Asthma Short Acting Beta Agonists Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 Anti Asthma Short Acting Beta Agonists Market Production by Region
9.1 Global Production of Anti Asthma Short Acting Beta Agonists by Region(2020-2025)
9.2 Global Anti Asthma Short Acting Beta Agonists Revenue Market Share by Region (2020-2025)
9.3 Global Anti Asthma Short Acting Beta Agonists Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Anti Asthma Short Acting Beta Agonists Production
9.4.1 North America Anti Asthma Short Acting Beta Agonists Production Growth Rate (2020-2025)
9.4.2 North America Anti Asthma Short Acting Beta Agonists Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Anti Asthma Short Acting Beta Agonists Production
9.5.1 Europe Anti Asthma Short Acting Beta Agonists Production Growth Rate (2020-2025)
9.5.2 Europe Anti Asthma Short Acting Beta Agonists Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Anti Asthma Short Acting Beta Agonists Production (2020-2025)
9.6.1 Japan Anti Asthma Short Acting Beta Agonists Production Growth Rate (2020-2025)
9.6.2 Japan Anti Asthma Short Acting Beta Agonists Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Anti Asthma Short Acting Beta Agonists Production (2020-2025)
9.7.1 China Anti Asthma Short Acting Beta Agonists Production Growth Rate (2020-2025)
9.7.2 China Anti Asthma Short Acting Beta Agonists Production, Revenue, Price and Gross Margin (2020-2025)
10 Key Companies Profile
10.1 GlaxoSmithKline_x000D_
10.1.1 GlaxoSmithKline_x000D_ Basic Information
10.1.2 GlaxoSmithKline_x000D_ Anti Asthma Short Acting Beta Agonists Product Overview
10.1.3 GlaxoSmithKline_x000D_ Anti Asthma Short Acting Beta Agonists Product Market Performance
10.1.4 GlaxoSmithKline_x000D_ Business Overview
10.1.5 GlaxoSmithKline_x000D_ SWOT Analysis
10.1.6 GlaxoSmithKline_x000D_ Recent Developments
10.2 AstraZeneca_x000D_
10.2.1 AstraZeneca_x000D_ Basic Information
10.2.2 AstraZeneca_x000D_ Anti Asthma Short Acting Beta Agonists Product Overview
10.2.3 AstraZeneca_x000D_ Anti Asthma Short Acting Beta Agonists Product Market Performance
10.2.4 AstraZeneca_x000D_ Business Overview
10.2.5 AstraZeneca_x000D_ SWOT Analysis
10.2.6 AstraZeneca_x000D_ Recent Developments
10.3 Teva Pharmaceutical_x000D_
10.3.1 Teva Pharmaceutical_x000D_ Basic Information
10.3.2 Teva Pharmaceutical_x000D_ Anti Asthma Short Acting Beta Agonists Product Overview
10.3.3 Teva Pharmaceutical_x000D_ Anti Asthma Short Acting Beta Agonists Product Market Performance
10.3.4 Teva Pharmaceutical_x000D_ Business Overview
10.3.5 Teva Pharmaceutical_x000D_ SWOT Analysis
10.3.6 Teva Pharmaceutical_x000D_ Recent Developments
10.4 Pfizer_x000D_
10.4.1 Pfizer_x000D_ Basic Information
10.4.2 Pfizer_x000D_ Anti Asthma Short Acting Beta Agonists Product Overview
10.4.3 Pfizer_x000D_ Anti Asthma Short Acting Beta Agonists Product Market Performance
10.4.4 Pfizer_x000D_ Business Overview
10.4.5 Pfizer_x000D_ Recent Developments
10.5 Viatris_x000D_
10.5.1 Viatris_x000D_ Basic Information
10.5.2 Viatris_x000D_ Anti Asthma Short Acting Beta Agonists Product Overview
10.5.3 Viatris_x000D_ Anti Asthma Short Acting Beta Agonists Product Market Performance
10.5.4 Viatris_x000D_ Business Overview
10.5.5 Viatris_x000D_ Recent Developments
10.6 Novartis_x000D_
10.6.1 Novartis_x000D_ Basic Information
10.6.2 Novartis_x000D_ Anti Asthma Short Acting Beta Agonists Product Overview
10.6.3 Novartis_x000D_ Anti Asthma Short Acting Beta Agonists Product Market Performance
10.6.4 Novartis_x000D_ Business Overview
10.6.5 Novartis_x000D_ Recent Developments
10.7 Boehringer Ingelheim_x000D_
10.7.1 Boehringer Ingelheim_x000D_ Basic Information
10.7.2 Boehringer Ingelheim_x000D_ Anti Asthma Short Acting Beta Agonists Product Overview
10.7.3 Boehringer Ingelheim_x000D_ Anti Asthma Short Acting Beta Agonists Product Market Performance
10.7.4 Boehringer Ingelheim_x000D_ Business Overview
10.7.5 Boehringer Ingelheim_x000D_ Recent Developments
10.8 Sanofi_x000D_
10.8.1 Sanofi_x000D_ Basic Information
10.8.2 Sanofi_x000D_ Anti Asthma Short Acting Beta Agonists Product Overview
10.8.3 Sanofi_x000D_ Anti Asthma Short Acting Beta Agonists Product Market Performance
10.8.4 Sanofi_x000D_ Business Overview
10.8.5 Sanofi_x000D_ Recent Developments
10.9 Joincare Pharmaceutical Group Industry_x000D_
10.9.1 Joincare Pharmaceutical Group Industry_x000D_ Basic Information
10.9.2 Joincare Pharmaceutical Group Industry_x000D_ Anti Asthma Short Acting Beta Agonists Product Overview
10.9.3 Joincare Pharmaceutical Group Industry_x000D_ Anti Asthma Short Acting Beta Agonists Product Market Performance
10.9.4 Joincare Pharmaceutical Group Industry_x000D_ Business Overview
10.9.5 Joincare Pharmaceutical Group Industry_x000D_ Recent Developments
10.10 Chia Tai Tianqing Pharmaceutical Group_x000D_
10.10.1 Chia Tai Tianqing Pharmaceutical Group_x000D_ Basic Information
10.10.2 Chia Tai Tianqing Pharmaceutical Group_x000D_ Anti Asthma Short Acting Beta Agonists Product Overview
10.10.3 Chia Tai Tianqing Pharmaceutical Group_x000D_ Anti Asthma Short Acting Beta Agonists Product Market Performance
10.10.4 Chia Tai Tianqing Pharmaceutical Group_x000D_ Business Overview
10.10.5 Chia Tai Tianqing Pharmaceutical Group_x000D_ Recent Developments
10.11 Shandong Lunan Pharmaceutical_x000D_
10.11.1 Shandong Lunan Pharmaceutical_x000D_ Basic Information
10.11.2 Shandong Lunan Pharmaceutical_x000D_ Anti Asthma Short Acting Beta Agonists Product Overview
10.11.3 Shandong Lunan Pharmaceutical_x000D_ Anti Asthma Short Acting Beta Agonists Product Market Performance
10.11.4 Shandong Lunan Pharmaceutical_x000D_ Business Overview
10.11.5 Shandong Lunan Pharmaceutical_x000D_ Recent Developments
10.12 Jiangsu Hengrui Pharmaceuticals_x000D_
10.12.1 Jiangsu Hengrui Pharmaceuticals_x000D_ Basic Information
10.12.2 Jiangsu Hengrui Pharmaceuticals_x000D_ Anti Asthma Short Acting Beta Agonists Product Overview
10.12.3 Jiangsu Hengrui Pharmaceuticals_x000D_ Anti Asthma Short Acting Beta Agonists Product Market Performance
10.12.4 Jiangsu Hengrui Pharmaceuticals_x000D_ Business Overview
10.12.5 Jiangsu Hengrui Pharmaceuticals_x000D_ Recent Developments
10.13 Sichuan Puretech Pharmaceutical
10.13.1 Sichuan Puretech Pharmaceutical Basic Information
10.13.2 Sichuan Puretech Pharmaceutical Anti Asthma Short Acting Beta Agonists Product Overview
10.13.3 Sichuan Puretech Pharmaceutical Anti Asthma Short Acting Beta Agonists Product Market Performance
10.13.4 Sichuan Puretech Pharmaceutical Business Overview
10.13.5 Sichuan Puretech Pharmaceutical Recent Developments
11 Anti Asthma Short Acting Beta Agonists Market Forecast by Region
11.1 Global Anti Asthma Short Acting Beta Agonists Market Size Forecast
11.2 Global Anti Asthma Short Acting Beta Agonists Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Anti Asthma Short Acting Beta Agonists Market Size Forecast by Country
11.2.3 Asia Pacific Anti Asthma Short Acting Beta Agonists Market Size Forecast by Region
11.2.4 South America Anti Asthma Short Acting Beta Agonists Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Anti Asthma Short Acting Beta Agonists by Country
12 Forecast Market by Type and by Application (2026-2033)
12.1 Global Anti Asthma Short Acting Beta Agonists Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Anti Asthma Short Acting Beta Agonists by Type (2026-2033)
12.1.2 Global Anti Asthma Short Acting Beta Agonists Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Anti Asthma Short Acting Beta Agonists by Type (2026-2033)
12.2 Global Anti Asthma Short Acting Beta Agonists Market Forecast by Application (2026-2033)
12.2.1 Global Anti Asthma Short Acting Beta Agonists Sales (K MT) Forecast by Application
12.2.2 Global Anti Asthma Short Acting Beta Agonists Market Size (M USD) Forecast by Application (2026-2033)
13 Conclusion and Key Findings
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.